Crispr Therapeutics Ag
(CRSP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -450,986 | -344,545 | -135,996 | -366,252 | -328,941 |
| Depreciation Amortization | 13,818 | 9,385 | 4,736 | 19,259 | 14,417 |
| Accounts receivable | 25,000 | 25,000 | 25,000 | 175,000 | 200,000 |
| Other Working Capital | 49,245 | 38,336 | 54,848 | 156,270 | 180,624 |
| Other Operating Activity | 110,462 | 103,997 | -2,535 | -127,051 | -158,843 |
| Operating Cash Flow | $-252,461 | $-167,827 | $-53,947 | $-142,774 | $-92,743 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -33,907 | 85,245 | -14,549 | -255,397 | -364,277 |
| PPE Investments | -397 | -323 | -206 | -1,901 | -1,647 |
| Purchase Of Investment | -9,700 | -9,700 | -5,000 | -23,183 | -20,385 |
| Other Investing Activity | -25,000 | -25,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-69,004 | $50,222 | $-19,755 | $-280,481 | $-386,309 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 309,612 | 12,846 | 10,588 | 331,984 | 315,108 |
| Financing Cash Flow | $309,612 | $12,846 | $10,588 | $331,984 | $315,108 |
| Exchange Rate Effect | 94 | 121 | 41 | -21 | 66 |
| Beginning Cash Position | 309,776 | 309,776 | 309,776 | 401,068 | 401,068 |
| End Cash Position | 298,017 | 205,138 | 246,703 | 309,776 | 237,190 |
| Net Cash Flow | $-11,759 | $-104,638 | $-63,073 | $-91,292 | $-163,878 |
| Free Cash Flow | |||||
| Operating Cash Flow | -252,461 | -167,827 | -53,947 | -142,774 | -92,743 |
| Capital Expenditure | -397 | -323 | -206 | -1,901 | -1,647 |
| Free Cash Flow | -252,858 | -168,150 | -54,153 | -144,675 | -94,390 |